Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Receivables - Other: 2011-2016

Historic Receivables - Other for Northwest Biotherapeutics (NWBO) over the last 2 years, with Sep 2016 value amounting to $700,000.

  • Northwest Biotherapeutics' Receivables - Other fell 41.67% to $700,000 in Q3 2016 from the same period last year, while for Sep 2016 it was $700,000, marking a year-over-year decrease of 41.67%. This contributed to the annual value of $1.2 million for FY2015, which is N/A change from last year.
  • Latest data reveals that Northwest Biotherapeutics reported Receivables - Other of $700,000 as of Q3 2016, which was down 30.00% from $1.0 million recorded in Q2 2016.
  • Northwest Biotherapeutics' 5-year Receivables - Other high stood at $4.8 million for Q3 2012, and its period low was $700,000 during Q3 2016.
  • For the 3-year period, Northwest Biotherapeutics' Receivables - Other averaged around $1.4 million, with its median value being $1.2 million (2015).
  • Data for Northwest Biotherapeutics' Receivables - Other shows a maximum YoY tumbled of 54.29% (in 2015) over the last 5 years.
  • Quarterly analysis of 4 years shows Northwest Biotherapeutics' Receivables - Other stood at $4.8 million in 2012, then reached $2.6 million in 2014, then crashed by 54.29% to $1.2 million in 2015, then slumped by 41.67% to $700,000 in 2016.
  • Its Receivables - Other stands at $700,000 for Q3 2016, versus $1.0 million for Q2 2016 and $1.0 million for Q1 2016.